NCT01683773已完成1 期
A Phase I, Open Label Trial to Evaluate the Safety and Immunogenicity of AERAS-402 Followed by MVA85A in BCG Vaccinated Adults (TB032)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 4
- 主要终点
- Safety of AERAS-402 followed by MVA85A
研究概览
简要总结
This trial will investigate the administration of two new tuberculosis vaccines, called AERAS-402 and MVA85A. The purpose of this trial is to assess what happens when both of these vaccines are given one after the other. The trial will assess the safety of both vaccines and also their ability to stimulate an immune response within the body. It is hoped that when these two vaccines are given in sequence, the combined immune response is even better than when each vaccine is used individually.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects must meet all of the following criteria to enter the trial:
- •Healthy adult aged 18-55 years
- •Resident in or near Oxford (for CCVTM) or Birmingham (for WTCRF; and able to travel to Oxford for vaccinations) for the duration of the trial period
- •No relevant findings in medical history or on physical examination
- •Confirmation of prior vaccination with BCG not less than 6 months prior to projected trial vaccination date (by visible BCG scar on examination or written documentation)
- •Allow the Investigators to discuss the individual's medical history with their GP
- •Use effective contraception for the duration of the trial period (females only)
- •Refrain from blood donation during the trial
- •Give written informed consent
- •Allow the Investigator to register subject details with a confidential database to prevent concurrent entry into clinical trials
- •Agrees to avoid elective surgery for the duration of the trial
- •Has a body mass index (BMI) between 18 and 33 (weight/height2) by nomogram
- •Able and willing (in the Investigator's opinion) to comply with all the trial requirements
排除标准
- •Subjects must meet none of the following criteria to enter the trial:
- •Laboratory evidence at screening of latent M. tb infection as indicated by a positive ELISPOT response to ESAT6 or CFP10 antigens
- •Clinical, radiological, or laboratory evidence of current active TB disease
- •Shared a residence within one year prior to day 0 with an individual on anti-tuberculosis treatment or with culture- or smear-positive pulmonary tuberculosis
- •Previous treatment for active or latent tuberculosis infection
- •Received a TST within 90 days prior to day 0
- •Received a systemic antibiotic within 14 days prior to day 0
- •Inability to discontinue daily medications other than the following during the trial: oral contraceptives, vitamins, nonprescription nutritional supplements, aspirin, antihistamines, antihypertensives, antidepressants, inhaled steroids, bronchodilators, and any other stable, regular medication not deemed to have an impact on safety or immunogenicity.
- •Previous vaccination with candidate vaccine MVA85A or candidate vaccine FP85A or any other recombinant MVA or adenoviral vaccine; AERAS-402; or any other investigational M. tb vaccine
- •Clinically significant history of skin disorder, allergy, immunodeficiency (including HIV), autoimmune disease, cancer (except BCC or CIS), cardiovascular disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, neurological illness, psychiatric disorder, drug or alcohol abuse
- •History of serious psychiatric condition
- •Concurrent oral or systemic steroid medication or the concurrent use of other immunosuppressive agents
- •History of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine, including eggs
- •Any abnormality of screening blood or urine tests that is deemed to be clinically significant or that may compromise the safety of the subject in the triala
- •Positive HBsAg, HCV or HIV antibodies
- •Female currently lactating, confirmed pregnancy or intention to become pregnant during trial period
- •Use of an investigational medicinal product or non-registered drug, live vaccine, or medical device other than the trial vaccine for 30 days prior to dosing with the trial vaccine, or planned use during the trial period
- •Administration of immunoglobulins and/or any blood products within the three months preceding the planned trial vaccination date
- •Any other significant disease, disorder, or finding, which, in the opinion of the Investigator, may either put the subject at risk or may influence the result of the trial or may affect the subject's ability to participate in the trial
结局指标
主要结局
Safety of AERAS-402 followed by MVA85A
时间窗: 3 months after final vaccination
To evaluate the safety profile of multiple doses of AERAS-402 alone, compared to one and two doses of AERAS-402 followed by MVA85A in healthy, BCG vaccinated adults, measured by number and severity of local and systemic adverse events
次要结局
- Immunogenicity of AERAS-402 followed by MVA85A(12-18 months after first vaccination)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
A Phase I Study to Assess the Safety and Immunogenicity of Tuberculosis (TB) Vaccine Candidates FP85A and MVA85ATuberculosisNCT00653770University of Oxford31
终止
1 期
MVA85A Aerosol vs Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M. tb) InfectionTuberculosisNCT02532036University of Oxford2
已完成
1 期
Clinical Trial to Study 4 Different Doses of the Vaccine RUTI in Healthy VolunteersLatent Tuberculosis InfectionTuberculosisNCT00546273Germans Trias i Pujol Hospital24
进行中（未招募）
1 期
Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M AdjuvantPlasmodium Falciparum MalariaNCT06549257University of Oxford56
已完成
1 期
Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in Children With MDR-TB With and Without HIVTuberculosisHIV InfectionsNCT03141060National Institute of Allergy and Infectious Diseases (NIAID)37